Digital health startups to watch:
Biofourmis raised more venture capital funding than any other medical device developer last year with its $320 million Series D round. Last February, the company launched Biofourmis Care, offering remote care for patients with heart failure, hypertension, diabetes, lipid management or atrial fibrillation.
The software-as-a-medical-device (SaMD) developer has FDA 510(k) clearances for its Biovitals Analytics Engine and RhythmAnalytics devices, which use proprietary algorithms to measure and analyze health data.
Biofourmis CEO Kuldeep Singh Rajput said in January that the company is “building a specialty network of physicians” as its second go-to-market strategy. “We see ourselves in the future as a provider,” he told Axios at the J.P. Morgan Healthcare Conference.
Most recently, the company entered into a partnership with Chugai Pharmaceutical Co. in March to objectively measure pain in endometriosis patients.